Rucaparib clinical trials
Also written Rubraca, CO-338 and PF 01367338.
ClinicalTrials.gov finds 70 studies for rucaparib. How that becomes 58 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives rucaparib. Its counts are asked again every night. How drug pages count
- 70Found by its intervention search · See all 70 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 65 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedNCT07674368 · A mistranslated title; the study tests recaticimabReport a problem
- 69Give rucaparib to participants
- −5Observe patients on it, or give it outside a trial
- −6Give it beside what is tested
- 58Test it: the count on this site
Get an email when these change. Save the rucaparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Dec 2016 · RUBRACA · NDA 209115 (FDA, Drugs@FDA)
- European Union
- 23 May 2018 · Rubraca · EMEA/H/C/004272 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Rucaparib
- 49
- Rucaparib camsylate
- 6
- 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
- 2
- 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
- 2
- 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt
- 2
Brand
- Rubraca
- 21
Studies by the year they started
58 studies that test it; most in 2019 (15)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 13 |
| 2019 | 15 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 33
pharmaand GmbH (20) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (2) · University of Michigan Rogel Cancer Center (2) · Dana-Farber Cancer Institute (1) · Alliance for Clinical Trials in Oncology (1) · Royal Marsden NHS Foundation Trust (1) · Brown University (1)
Often tested with
Tested in the same studies.
Nivolumab (11) · Bevacizumab (6) · Atezolizumab (5) · Capecitabine (2) · Durvalumab (2) · Trastuzumab (2) · Fluorouracil (2) · Docetaxel (2)
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 4 most studied
New when their studies opened, with rucaparib beside them; studies of each.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test rucaparib, phase 3 first.
- Mar 2027A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyPhase 3 · Alliance for Clinical Trials in Oncology
- Jan 2027A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerPhase 1/2 · Brown University
- Jun 2027Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerPhase 1 · Brigham and Women's Hospital
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses rucaparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 58
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Continued, alone or with nivolumab, in a rollover studyWritten as RucaparibReport a problem
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingPhase 1Brigham and Women's HospitalNCT04701645One of many drugs released in microdoses by an implanted deviceReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as RucaparibReport a problem
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyTerminatedPhase 2University of WashingtonNCT03442556After docetaxel and carboplatin in prostate cancer with DNA repair deficiencyWritten as Rucaparib CamsylateReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833One arm, for BAP1- or BRCA1-negative mesotheliomaWritten as RucaparibReport a problem
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04624178With nivolumab in leiomyosarcomaWritten as RucaparibReport a problem
- The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedPhase 2Medical College of WisconsinNCT03694262With bevacizumab and atezolizumab in endometrial cancerWritten as RucaparibReport a problem
- A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02873962Added to nivolumab and bevacizumab in relapsed ovarian cancerWritten as RucaparibReport a problem
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedPhase 2University of Colorado, DenverNCT03617679Against placebo as maintenance in endometrial cancerWritten as RucaparibReport a problem
- Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT03559049With pembrolizumab as maintenance in non-squamous lung cancerWritten as RucaparibReport a problem
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04455750Added to enzalutamide, against placebo, in prostate cancerWritten as Rucaparib camsylateReport a problem
- An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedPhase 2Bristol-Myers SquibbNCT03338790With nivolumab in castration-resistant prostate cancerWritten as rucaparibReport a problem
- A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03542175With radiotherapy in triple-negative breast cancer left after chemotherapyWritten as RucaparibReport a problem
- Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04276376With atezolizumab in DNA repair-deficient or platinum-sensitive tumoursWritten as RucaparibReport a problem
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 3pharmaand GmbHNCT02975934On the US labelAgainst physician's choice in prostate cancer with DNA repair gene changesWritten as RucaparibReport a problem
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingPhase 3pharmaand GmbHNCT03522246With or without nivolumab as first maintenance in ovarian cancerWritten as RucaparibReport a problem
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT02678182One maintenance arm in oesophago-gastric cancerWritten as RucaparibReport a problem
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedPhase 2University of Michigan Rogel Cancer CenterNCT03639935With nivolumab after platinum in biliary tract cancerWritten as RucaparibReport a problem
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedPhase 2SWOG Cancer Research NetworkNCT03845296Alone in lung cancer with high LOH or BRCA mutationWritten as RucaparibReport a problem
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1/2Brown UniversityNCT04253262With copanlisib in castration-resistant prostate cancerWritten as RucaparibReport a problem
See all 58 studies that test rucaparib →
Behind its US label · 3 — the studies the FDA label of RUBRACA describes
From the Clinical Studies section of RUBRACA (2026-10), as openFDA has it. A study the site does not hold is left out.
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedPhase 3pharmaand GmbHNCT01968213Report a problem
- A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 2pharmaand GmbHNCT02952534Report a problem
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 3pharmaand GmbHNCT02975934Report a problem
Tested on its own · 24 — no other medicine in its arm
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedPhase 2University of Colorado, DenverNCT03617679Against placebo as maintenance in endometrial cancerWritten as RucaparibReport a problem
- A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03542175With radiotherapy in triple-negative breast cancer left after chemotherapyWritten as RucaparibReport a problem
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 3pharmaand GmbHNCT02975934On the US labelAgainst physician's choice in prostate cancer with DNA repair gene changesWritten as RucaparibReport a problem
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedPhase 2SWOG Cancer Research NetworkNCT03845296Alone in lung cancer with high LOH or BRCA mutationWritten as RucaparibReport a problem
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedPhase 3North Eastern German Society of Gynaecological OncologyNCT04227522Against placebo as maintenance after bevacizumab in ovarian cancerWritten as RucaparibReport a problem
- Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03413995Alone in hormone-sensitive prostate cancer with inherited DNA repair mutationsWritten as RucaparibReport a problem
- Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsCompletedEarly Phase 1University of ArizonaNCT03911453Alone before surgery, to see its effect on PD-L1Written as RucaparibReport a problem
- CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedPhase 3pharmaand GmbHNCT04676334Continued for people still benefiting from earlier studiesWritten as RucaparibReport a problem
- Rucaparib in Nonmetastatic prOstAte With BRCAnessTerminatedPhase 2University of UtahNCT03533946Alone in non-metastatic prostate cancer with BRCAnessWritten as RucaparibReport a problem
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesTerminatedPhase 2pharmaand GmbHNCT04171700Alone in solid tumours with HRR gene mutationsWritten as RucaparibReport a problem
- Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyTerminatedPhase 2Abramson Cancer Center at Penn MedicineNCT03140670Maintenance in BRCA- or PALB2-mutated pancreatic cancerWritten as RUCAPARIBReport a problem
- A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedPhase 2pharmaand GmbHNCT02042378Alone in BRCA-mutated pancreatic cancerWritten as RucaparibReport a problem
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedPhase 2pharmaand GmbHNCT01891344Alone in relapsed ovarian cancer, by DNA repair statusWritten as Oral rucaparibReport a problem
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedPhase 3pharmaand GmbHNCT02855944Against chemotherapy in BRCA-mutated ovarian cancerWritten as RucaparibReport a problem
- A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorCompletedPhase 1pharmaand GmbHNCT03499444Alone, dose finding in Japanese patientsWritten as RucaparibReport a problem
- A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 2pharmaand GmbHNCT02952534On the US labelAlone in prostate cancer with DNA repair gene changesWritten as RucaparibReport a problem
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedPhase 3pharmaand GmbHNCT01968213On the US labelAgainst placebo as maintenance in ovarian cancerWritten as RucaparibReport a problem
- Rucaparib Hepatic Impairment Study in Patients With a Solid TumorCompletedPhase 1pharmaand GmbHNCT03521037Single dose in people with liver impairmentWritten as Rucaparib camsylateReport a problem
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedPhase 1/2pharmaand GmbHNCT01482715Alone, dose finding and in BRCA-mutated ovarian cancerWritten as RucaparibReport a problem
- Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedPhase 2pharmaand GmbHNCT03397394Alone in advanced urothelial cancerWritten as RucaparibReport a problem
Showing 20 of 24. See all 24 →
Tested with established drugs · 6 — they are given beside it
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04455750Added to enzalutamide, against placebo, in prostate cancerWritten as Rucaparib camsylateReport a problem
- PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsCompletedPhase 2Hoosier Cancer Research NetworkNCT01074970Added to cisplatin after chemotherapy in BRCA-mutated triple-negative breast cancerWritten as RucaparibReport a problem
- Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)CompletedPhase 1pharmaand GmbHNCT04179396With enzalutamide or abiraterone in prostate cancerWritten as RucaparibReport a problem
- Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-RucaparibCompletedPhase 1pharmaand GmbHNCT02986100Radiolabelled dose to trace how the body handles itWritten as RucaparibReport a problem
- A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic RegimensCompletedPhase 1pharmaand GmbHNCT01009190With carboplatin, first dose-finding studyWritten as PF-01367338Report a problem
- Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairCompletedPhase 1Pamela MunsterNCT03318445With irinotecan in cancers with DNA repair mutationsWritten as RucaparibReport a problem
Tested in a combination · 28 — another drug in the study is under test too
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Continued, alone or with nivolumab, in a rollover studyWritten as RucaparibReport a problem
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingPhase 1Brigham and Women's HospitalNCT04701645One of many drugs released in microdoses by an implanted deviceReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as RucaparibReport a problem
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyTerminatedPhase 2University of WashingtonNCT03442556After docetaxel and carboplatin in prostate cancer with DNA repair deficiencyWritten as Rucaparib CamsylateReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833One arm, for BAP1- or BRCA1-negative mesotheliomaWritten as RucaparibReport a problem
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04624178With nivolumab in leiomyosarcomaWritten as RucaparibReport a problem
- The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedPhase 2Medical College of WisconsinNCT03694262With bevacizumab and atezolizumab in endometrial cancerWritten as RucaparibReport a problem
- A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02873962Added to nivolumab and bevacizumab in relapsed ovarian cancerWritten as RucaparibReport a problem
- Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT03559049With pembrolizumab as maintenance in non-squamous lung cancerWritten as RucaparibReport a problem
- An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedPhase 2Bristol-Myers SquibbNCT03338790With nivolumab in castration-resistant prostate cancerWritten as rucaparibReport a problem
- Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04276376With atezolizumab in DNA repair-deficient or platinum-sensitive tumoursWritten as RucaparibReport a problem
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingPhase 3pharmaand GmbHNCT03522246With or without nivolumab as first maintenance in ovarian cancerWritten as RucaparibReport a problem
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT02678182One maintenance arm in oesophago-gastric cancerWritten as RucaparibReport a problem
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedPhase 2University of Michigan Rogel Cancer CenterNCT03639935With nivolumab after platinum in biliary tract cancerWritten as RucaparibReport a problem
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1/2Brown UniversityNCT04253262With copanlisib in castration-resistant prostate cancerWritten as RucaparibReport a problem
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT03552471With mirvetuximab soravtansine in recurrent gynaecologic cancersWritten as Rucaparib CamsylateReport a problem
- Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedPhase 2Zhonglin HaoNCT03958045With nivolumab as maintenance in small cell lung cancerWritten as Rucaparib and NivolumabReport a problem
- Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerActive, not recruitingPhase 1/2Academic and Community Cancer Research UnitedNCT03337087With liposomal irinotecan and fluorouracil in digestive cancersWritten as RucaparibReport a problem
- Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumCompletedPhase 2University of OklahomaNCT03476798With bevacizumab in recurrent cervical or endometrial cancerWritten as RucaparibReport a problem
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedPhase 1/2pharmaand GmbHNCT03992131With lucitanib or sacituzumab govitecan in solid tumoursWritten as RucaparibReport a problem
Showing 20 of 28. See all 28 →
Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with rucaparib: DFP-13318 1 · Pegylated SN-38 Conjugate PLX038 1 · ipatasertib 1 · INCB057643 1
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Continued with atezolizumab, as in the earlier studyWritten as RucaparibReport a problem
- PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04209595In every armGiven with PLX038, the drug being dosedWritten as RucaparibReport a problem
- Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02711137Given with INCB057643 in one combination groupWritten as RucaparibReport a problem
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT04826198In every armThe PARP inhibitor AsiDNA is added toWritten as RucaparibReport a problem
- A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.CompletedPhase 1Hoffmann-La RocheNCT03840200In every armGiven with ipatasertib, the drug being dosedWritten as RucaparibReport a problem
Beside supportive care · 1 — a supportive treatment or test is studied
Observed · 5 — patients on it are followed, or it is given outside a trial
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNovartis PharmaceuticalsNCT07477756One possible treatment after 177Lu-PSMA-617, looked back onReport a problem
- Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyCompletedGrupo Español de Investigación en Cáncer de OvarioNCT04539327Spanish access programme, looked back onWritten as RucaparibReport a problem
- Arterial Hypertension Related to PARP Inhibitors (ArteRIB)CompletedUniversity Hospital, CaenNCT04774406One PARP inhibitor in reports of high blood pressureWritten as olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparibReport a problem
- Pancytopenia Related to PARP Inhibitors (PancytoRIB)CompletedUniversity Hospital, CaenNCT04774627One PARP inhibitor in reports of pancytopeniaReport a problem
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)CompletedUniversity Hospital, CaenNCT04326023One PARP inhibitor in reports of MDS and AMLReport a problem
Codes
What other systems call rucaparib · ClinicalTrials.gg INT005325
- MeSH (NLM) C531549rucaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8237F3U7EHRUCAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1862579Confirmed FDA, Wikidata
- Wikidata Q7376558rucaparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C137800RucaparibConfirmed FDA, Wikidata
- DrugBank DB12332One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531549 | rucaparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8237F3U7EH | RUCAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1862579 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7376558 | rucaparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C137800 | Rucaparib | Confirmed FDA, Wikidata |
| DrugBank | DB12332 | — | One source Wikidata |
Also registered as rucaparib camsylate (UNII 41AX9SJ8KO · RxNorm 1862578) and rucaparib phosphate (UNII H3M9955244).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.